1. Home
  2. QLYS vs CYTK Comparison

QLYS vs CYTK Comparison

Compare QLYS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLYS
  • CYTK
  • Stock Information
  • Founded
  • QLYS 1999
  • CYTK 1997
  • Country
  • QLYS United States
  • CYTK United States
  • Employees
  • QLYS N/A
  • CYTK N/A
  • Industry
  • QLYS Computer Software: Prepackaged Software
  • CYTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • QLYS Technology
  • CYTK Health Care
  • Exchange
  • QLYS Nasdaq
  • CYTK Nasdaq
  • Market Cap
  • QLYS 4.7B
  • CYTK 4.6B
  • IPO Year
  • QLYS 2012
  • CYTK 2004
  • Fundamental
  • Price
  • QLYS $127.31
  • CYTK $58.82
  • Analyst Decision
  • QLYS Hold
  • CYTK Buy
  • Analyst Count
  • QLYS 15
  • CYTK 16
  • Target Price
  • QLYS $141.00
  • CYTK $76.73
  • AVG Volume (30 Days)
  • QLYS 345.7K
  • CYTK 2.1M
  • Earning Date
  • QLYS 11-04-2025
  • CYTK 11-05-2025
  • Dividend Yield
  • QLYS N/A
  • CYTK N/A
  • EPS Growth
  • QLYS 10.84
  • CYTK N/A
  • EPS
  • QLYS 5.02
  • CYTK N/A
  • Revenue
  • QLYS $637,019,000.00
  • CYTK $85,738,000.00
  • Revenue This Year
  • QLYS $10.77
  • CYTK $363.61
  • Revenue Next Year
  • QLYS $6.64
  • CYTK $64.08
  • P/E Ratio
  • QLYS $25.45
  • CYTK N/A
  • Revenue Growth
  • QLYS 9.63
  • CYTK 2635.74
  • 52 Week Low
  • QLYS $112.61
  • CYTK $29.31
  • 52 Week High
  • QLYS $170.00
  • CYTK $63.86
  • Technical
  • Relative Strength Index (RSI)
  • QLYS 37.28
  • CYTK 61.45
  • Support Level
  • QLYS $125.75
  • CYTK $58.84
  • Resistance Level
  • QLYS $130.59
  • CYTK $63.86
  • Average True Range (ATR)
  • QLYS 3.02
  • CYTK 2.63
  • MACD
  • QLYS -0.42
  • CYTK -0.02
  • Stochastic Oscillator
  • QLYS 13.30
  • CYTK 63.24

About QLYS Qualys Inc.

Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: